MANKIND Stock Overview
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mankind Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,369.00 |
| 52 Week High | ₹2,490.00 |
| 52 Week Low | ₹1,242.00 |
| Beta | 0 |
| 1 Month Change | 1.40% |
| 3 Month Change | 16.68% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 66.56% |
Recent News & Updates
Mankind Pharma Limited's (NSE:MANKIND) Business Is Trailing The Market But Its Shares Aren't
Apr 08
Mankind Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 04Shareholder Returns
| MANKIND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.3% | 2.3% | 2.6% |
| 1Y | n/a | 56.7% | 45.0% |
Return vs Industry: Insufficient data to determine how MANKIND performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MANKIND performed against the Indian Market.
Price Volatility
| MANKIND volatility | |
|---|---|
| MANKIND Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: MANKIND has not had significant price volatility in the past 3 months.
Volatility Over Time: MANKIND's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 18,468 | Sheetal Arora | www.mankindpharma.com |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.
Mankind Pharma Limited Fundamentals Summary
| MANKIND fundamental statistics | |
|---|---|
| Market cap | ₹948.99b |
| Earnings (TTM) | ₹17.27b |
| Revenue (TTM) | ₹99.46b |
54.9x
P/E Ratio9.5x
P/S RatioIs MANKIND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MANKIND income statement (TTM) | |
|---|---|
| Revenue | ₹99.46b |
| Cost of Revenue | ₹32.36b |
| Gross Profit | ₹67.11b |
| Other Expenses | ₹49.84b |
| Earnings | ₹17.27b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.11 |
| Gross Margin | 67.47% |
| Net Profit Margin | 17.36% |
| Debt/Equity Ratio | 2.1% |
How did MANKIND perform over the long term?
See historical performance and comparison